Bizarre Patents
A hand wearable body squeegee comprising a glove portion, a concave squeegee band, and a linear squeegee band.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187591 | Methods of treating coagulopathy The invention provides compositions and methods for enhancing clearance of coagulation factors {e.g., VWF) and platelets from the blood stream of a patient in need thereof. The methods comprise administering to the patient a therapeutically effective amount of an ag... | 05/29/2012 |
| 7959914 | Methods of reducing extravasation of inflammatory cells A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate... | 06/14/2011 |
| 7939066 | Methods and compositions for the inhibition of growth of infectious and other mycotic organisms in the gut of mammalian and avian species A method for the prevention and treatment of fungal infections and, therefore, consequent invasive mycosis in mammalian and avian species is described. The invention comprises a combination of β-1,3(4)-endoglucanohydrolase, β-1,3(4)glucan, diatomaceous earth, mine... | 05/10/2011 |
| 7935336 | Highly functional enzyme having α-galactosidase activity The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated ... | 05/03/2011 |
| 7914782 | Enzymes for reduced immunological stress Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an anima... | 03/29/2011 |
| 7901676 | Therapeutic composition for the treatment of rheumatoid arthritis A therapeutic composition and a method for rheumatoid arthritis is described. The composition comprises purified beta-glucuronidase at a concentration of between 200 and 10,000 Fishman units/ml and purified collagen at a concentration of between 0.5 and 2.5 mg/ml. T... | 03/08/2011 |
| 7846430 | Composition and method for treating bovine papilloma virus in equine A composition of lysozyme and a pharmaceutically acceptable carrier is active against the papilloma virus in both humans and animals. The composition can be used to treat women suffering from cervical cancer. The composition can also be used to treat cows and horses... | 12/07/2010 |
| 7655226 | Treatment of Pompe's disease The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient. ... | 02/02/2010 |
| 7635471 | Xylanase gene sequences from the genomic DNA of unpurified rumen microorganisms A xylanase gene, denoted xynR8, encoding a xylanase (XynR8) obtained from the unisolated rumen microorganisms is provided. The DNA sequence of the xynR8 gene, xylanase, is also provided, the enzyme is thermostable, and highly specific for xylans with high activity. ... | 12/22/2009 |
| 7485295 | Compositions and methods of using chondroitinase ABCI mutants One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using... | 02/03/2009 |
| 7442372 | Delivery of therapeutic compounds to the brain and other tissues The present invention relates to the intrathecal (IT) administration of recombinant enzyme to treat lysosomal storage disorders. In an exemplary embodiment, intrathecal administration of human α-L-iduronidase (rhIDU) injections in MPS I affected animals resulted in... | 10/28/2008 |
| 7417021 | Biologically active conjugate of a biopolymer and therapeutic agent A biologically active conjugate is disclosed comprising a biopolymer and a therapeutic agent joined by a disulfide bond. The conjugate, when formulated in a pharmaceutical composition with a suitable carrier, has improved in vivo stability and activity, and can be t... | 08/26/2008 |
| 7364888 | Intratracheal administration of lysozyme with other therapeutic agents in the prevention and treatment of respiratory disorders The subject invention is directed to the prevention and treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme, either alone or in combination with other therapeutic agents. Applicable respiratory disorders include, but... | 04/29/2008 |
| 7361644 | Specific antagonist for both E- and P-selectins Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-med... | 04/22/2008 |
| 7354606 | Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors A nutritional supplement composition contains inhibitors of alpha-glucosidase and alpha-amylase substantially in the absence of lipase inhibitors. The composition can include touchi extract and phaseolamin as the alpha-glucosidase and alpha-amylase inhibitor, respec... | 04/08/2008 |
| 7354576 | Methods of treating diseases caused by deficiencies of recombinant α-L-iduronidase The present invention provides a formulation comprising a pharmaceutical composition comprising a human recombinant α-L-iduronidase or biologically active or muteins thereof with a purity of greater than 99%, or in combination with a pharmaceutically acceptable car... | 04/08/2008 |
| 7351410 | Treatment of Pompe's disease The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient. ... | 04/01/2008 |
| 7348000 | Therapeutic compositions and methods of treating glycolipid storage related disorders A method for treating a glycolipid storage-related disorder, comprising administering a therapeutically effective amount of an inhibitor of glycolipid synthesis in combination with an agent capable of increasing the rate of glycolipid degradation or in combination w... | 03/25/2008 |
| 7348301 | Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems A method for killing, preventing, or inhibiting the growth of microorganisms in an aqueous system or on a substrate capable of supporting a growth of microorganisms is provided by providing lysozyme, alone or in combination with a quaternary ammonium compound to the... | 03/25/2008 |
| 7335355 | Antimicrobial agent A method of identifying an agent that enhances the anti-microbial activity of cationic anti-microbial peptides by blocking the inhibitory effects of the proteinase/glycosaminoglycan pathway, which method comprises: (i) providing, as a first component, a cationic ant... | 02/26/2008 |
| 7329527 | Serine proteases from gram-positive microorganisms The present invention relates to the identification of novel serine proteases in Gram-positive microorganisms. The present invention provides the nuclei acid and amino acid sequences for the Bacillus subtilis serine proteases SP1, SP2, SP3, SP4 and SP5. The p... | 02/12/2008 |
| 7329526 | Serine proteases from-gram-positive microorganisms The present invention relates to the identification of novel serine proteases in Gram-positive microorganisms. The present invention provides the nuclei acid and amino acid sequences for the Bacillus subtilis serine proteases SP1, SP2, SP3, SP4 and SP5. The p... | 02/12/2008 |
| 7329525 | Serine proteases from gram-positive microorganisms The present invention relates to the identification of novel serine proteases in Gram-positive microorganisms. The present invention provides the nuclei acid and amino acid sequences for the Bacillus subtilis serine proteases SP1, SP2, SP3, SP4 and SP5. The p... | 02/12/2008 |
| 7326531 | Proteases from gram-positive organisms The present invention relates to the identification of novel metallo-proteases (MP) in Gram-positive microorganisms. The present invention provides the nucleic acid and amino acid sequences for Bacillus MP. The present invention also provides host cells havin... | 02/05/2008 |
| 7316920 | Serine proteases from gram-positive microorganisms The present invention relates to the identification of novel serine proteases in Gram-positive microorganisms. The present invention provides the nuclei acid and amino acid sequences for the Bacillus subtilis serine proteases SP1, SP2, SP3, SP4 and SP5. The p... | 01/08/2008 |
| 7294342 | Ectoparasite asphyxiator compositions and methods for their application Water-soluble or water-dispersible, substantially air-impermeable, pharmacologically acceptable, liquid barrier compositions for treating ectoparasite infestations on animal skin and hair, wherein the compositions contain at least one monohydric aralkyl alcohol to p... | 11/13/2007 |
| 7273847 | Peptides with antioxidant and antimicrobial properties Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides de... | 09/25/2007 |
| 7264932 | Nuclease inhibitor cocktail Methods and compositions for inhibiting and/or inactivating nucleases by using nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors. ... | 09/04/2007 |
| 7241442 | Method for producing proteins suitable for treating lysosomal storage disorders The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Prote... | 07/10/2007 |
| 7238656 | Protective factors against inflammation, burns and noxious stimuli Peptide factors isolated from skin following exposure to chemical or thermal injury and treatment with iodine preparations are capable of reducing or ameliorating the extent of injury when administered to other animals. Specific peptides, including fragments of hist... | 07/03/2007 |
| 7232678 | Identification of oligoadenylate synthetase-like genes The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical com... | 06/19/2007 |
| 7232576 | Throat lozenge for the treatment of Group A A lozenge for the treatment of Streptococcus Group A infections of the mouth, throat, and nasal passage is disclosed which comprises a lytic enzyme composition specific for Streptococcus Group A and a lozenge carrier for delivering the lytic enzyme. | 06/19/2007 |
| 7208311 | Catalytic domain of ADAM33 and methods of use thereof The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of g... | 04/24/2007 |
| 7192922 | Method of treating left ventricular dysfunction A method of treating a patient having heart failure due to LV systolic dysfunction with an LV ejection fraction less than 40%. The method includes the steps of administering to a patient in need thereof, a compound selected from the group consisting of GIP, GIP anal... | 03/20/2007 |
| 7189393 | Recombinant anti-tumor RNAse This invention provides for new recombinant ribonuclease proteins which are active when expressed by bacteria. This allows the recombinant ribonucleases of this invention to be fused in-frame with ligand binding moieties to form cytotoxic fusion proteins. Furthermor... | 03/13/2007 |
| 7189555 | Proteases from gram-positive organisms The present invention relates to the identification of novel metallo-proteases (MP) in Gram-positive microorganisms. The present invention provides the nucleic acid and amino acid sequences for Bacillus (MP). The present invention also provides host cells hav... | 03/13/2007 |
| 7166278 | Modified organs and cells for xenotransplantation It has been discovered that there are at least two significant antigens present on the cells of animal species such as pigs that elicit an immune or inflammatory response immediately upon implantation into humans or contact with human serum. The first is an α-galac... | 01/23/2007 |
| 7166298 | Genetic immunization with cationic lipids A method for immunization using genetic material is disclosed. Compositions for genetic immunization comprising cationic lipids and polynucleotides are also disclosed. Methods for using genetic immunization to produce polyclonal and monoclonal antibodies are also di... | 01/23/2007 |
| 7163793 | Nuclease inhibitor cocktail Methods and compositions for inhibiting and/or inactivating nucleases by employing nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors. The anti-nuclease antibodies of the present invention... | 01/16/2007 |
| 7160714 | Vegetable fiber-digesting agent and method of processing vegetable waste by using the same It is an object of the present invention to provide a process for decomposing vegetable waste materials easily, which solves problems such as the problem of treatment costs, the problem of energy, an environmental problem and the problem of time for treatment which ... | 01/09/2007 |
